MV Management XI’s Recursion Pharmaceuticals RXRX Stock Holding History

MV Management XI’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$6.03M	Sell	788,762 -1,183,146	-60%	-$11.8M	10.04%	2
2023 Q2	$14.7M	Hold	1,971,908	–	–	25.77%	2
2023 Q1	$13.2M	Hold	1,971,908	–	–	20.13%	2
2022 Q4	$15.2M	Hold	1,971,908	–	–	26.45%	2
2022 Q3	$21M	Hold	1,971,908	–	–	15.2%	3
2022 Q2	$16.1M	Hold	1,971,908	–	–	14.59%	3
2022 Q1	$14.1M	Hold	1,971,908	–	–	9.8%	3
2021 Q4	$33.8M	Buy	+1,971,908	New	+$37.1M	14.59%	3

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

MV Management XI's RXRX Position: Q3 2023 in Review

MV Management XI reduced its Recursion Pharmaceuticals (RXRX) stake by 60% in Q3 2023, selling an estimated $11.8M and leaving 788,762 shares worth $6.03M. The position accounts for 10.04% of the portfolio, ranked #2.

MV Management XI first reported a position in RXRX in Q4 2021 and has held it in 8 quarters since. The position peaked at $33.8M in Q4 2021. 192 funds tracked by Wall St. Rank hold RXRX as of Q3 2023.

MV Management XI held 788,762 shares of Recursion Pharmaceuticals worth $6.03M as of Q3 2023.
MV Management XI sold 1,183,146 Recursion Pharmaceuticals shares in Q3 2023, an estimated $11.8M.
Recursion Pharmaceuticals made up 10.04% of MV Management XI's portfolio in Q3 2023, its #2 holding.
MV Management XI first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 8 quarters since.
MV Management XI's Recursion Pharmaceuticals position peaked at $33.8M in Q4 2021.
192 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2023.

Based on MV Management XI's 13F filing for Q3 2023, filed 14 Nov 2023.